Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Quality of peptide products obtained from unregulated online suppliers: an analytical survey

Bhattacharyya S, Wang J, Kaplan RM. Journal of Pharmaceutical Sciences 2024

Document identifier
CEI-BR-057
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Bhattacharyya S, Wang J, Kaplan RM
Title
Quality of peptide products obtained from unregulated online suppliers: an analytical survey
Source
Journal of Pharmaceutical Sciences
Year
2024
Volume, issue, pages
113(4):1102–1110
Digital object identifier
not held by the Institute
PubMed identifier
not held by the Institute
Record type
Journal article
Institute identifier
CEI-BR-057

Institute note. Cited by the Institute as an indicative analytical survey; sample frame was not random. The digital object identifier previously carried on this record did not resolve and has been withdrawn. Journal and year are retained.

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: RetatrutideCompound monograph
Monograph: SurvodutideCompound monograph
Monograph: CJC-1295Compound monograph
Monograph: IpamorelinCompound monograph
Monograph: AOD-9604Compound monograph
Monograph: IGF-1 LR3Compound monograph
Monograph: BPC-157Compound monograph
Monograph: TB-500Compound monograph
Monograph: KPVCompound monograph
Monograph: MOTS-cCompound monograph
Monograph: 5-amino-1MQCompound monograph
Monograph: Melanotan-IICompound monograph
Standard CEI-MS-15: Protocol for independent third-party verification of a supplied…Methodological standard
Synthesis: Retatrutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Survodutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: CJC-1295 in growth hormone deficiency and growth-hormone secretagogue…Evidence synthesis
Synthesis: Retatrutide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Retatrutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Survodutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: CJC-1295 in growth hormone deficiency and growth-hormone secretagogue…Evidence synthesis
Synthesis: Retatrutide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Retatrutide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Survodutide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: CJC-1295 in growth hormone deficiency and growth-hormone secretagogue…Evidence synthesis
24 citing documents.

§1.3Subject tags

supply quality analytical

Compound Evidence Institute · CEI-BR-057 · https://compoundevidence.com/bibliography/kaplan2024/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.